Skip to main content
SpringerLink
Log in

Buprenorphine and methadone appear to be cost effective for opioid use disorders

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Onuoha EN, et al. Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review. Value in Health 24: 1068-1083, No. 7, Jul 2021. Available from: URL: http://doi.org/10.1016/j.jval.2020.12.023

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buprenorphine and methadone appear to be cost effective for opioid use disorders. PharmacoEcon Outcomes News 883, 6 (2021). https://doi.org/10.1007/s40274-021-7877-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7877-7

Search

Navigation